Linezolida Kabi (Linezolid)

Linezolida Kabi is an oxazolidinone antibiotic indicated for serious infections caused by Gram‑positive bacteria.

• Complicated skin and soft tissue infections: effective against MRSA and other Gram‑positive pathogens, helping to resolve infection and prevent spread.
• Community‑acquired and nosocomial pneumonia: eradicates susceptible bacteria in the lungs, improving respiratory function.
• Infections caused by Gram‑positive bacteria such as VRE: provides a therapeutic option when other agents fail, targeting resistant strains.

• Linezolid binds to the 50S subunit of bacterial ribosomes, preventing the formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth by blocking translation, leading to a bacteriostatic effect against susceptible Gram‑positive organisms.

Linezolida Kabi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste perception.
• Vomiting: occasional emesis.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count requiring monitoring.
• Anemia: reduced red blood cell levels, potentially leading to fatigue.
• Peripheral neuropathy: nerve damage causing tingling or numbness.
• Optic neuropathy: visual disturbances that may be irreversible.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Myelosuppression: bone‑marrow suppression affecting multiple blood cell lines.

Before initiating therapy with Linezolida Kabi, several safety considerations should be observed.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic dysfunction: assess liver enzymes regularly during treatment.
• Concomitant serotonergic agents: avoid or closely monitor for serotonin syndrome.
• Prolonged therapy (>2 weeks): perform periodic complete blood counts to detect myelosuppression.
• Pregnancy and lactation: prescribe only if the potential benefit outweighs the risk to the fetus or infant.
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Linezolida Kabi can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• MAO inhibitors: may cause hypertensive crisis.
• Serotonergic antidepressants (SSRIs, SNRIs, TCAs, MAOIs): increased risk of serotonin syndrome.
• Rifampicin: reduces linezolid plasma concentrations, potentially lowering efficacy.
• Warfarin: may potentiate anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely)

• NSAIDs: heightened bleeding risk when combined with thrombocytopenia.
• Carbamazepine: may decrease linezolid levels, requiring efficacy monitoring.
• Digoxin: possible increase in serum digoxin concentrations.
• Oral contraceptives: may reduce hormonal effectiveness, advise alternative contraception.